Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial. The MIRASOL ...
Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback